Actualités

What is the potential for abuse of lisdexamfetamine in adults? A preclinical and clinical literature review and expert opinion

Carton L, Icick R, Weibel S, Dematteis M, Kammerer E, Batisse A, Rolland B. What is the potential for abuse of lisdexamfetamine in adults? A preclinical and clinical literature review and expert opinion. Expert Rev Clin Pharmacol. 2022 Aug 18:1-5. doi: 10.1080/17512433.2022.2112950. Epub ahead of print. PMID: 35959655.

Did the New French Regulation of Zolpidem Decrease the Problematic Consumption of Zolpidem? A Field Study among Users.

Laforgue EJ, Rousselet M, Claudon A, Aquizerate A, Jolliet P, Istvan M, Victorri-Vigneau C. Did the New French Regulation of Zolpidem Decrease the Problematic Consumption of Zolpidem? A Field Study among Users. Int J Environ Res Public Health. 2022 Jul 22;19(15):8920. doi: 10.3390/ijerph19158920. PMID: 35897285; PMCID: PMC9331950.

Hospitalisations après consommation de substances psychoactives pendant la pandémie de Covid-19

Dumoulin C, Ong N, Ramaroson H, Létinier L, Miremont-Salamé G, Gilleron V, Daveluy A, Perino J. Hospitalisations après consommation de substances psychoactives pendant la pandémie de Covid-19 [Hospitalizations after substance use during the COVID-19 pandemic]. Therapie. 2022 Jun 30:S0040-5957(22)00108-1. French. doi: 10.1016/j.therap.2022.06.003. Epub ahead of print. PMID: 35908997;  PMCID: PMC9329723. 

Communiqué – Augmentation des complications sanitaires graves associées à l’usage non médical du protoxyde d’azote en France

Communiqué de l’Association Française des Centres d’Addictovigilance du 23 juin 2022. L’Association Française des Centres d’Addictovigilance alerte sur les caractéristiques cliniques et l’ampleur des complications sanitaires graves avec l’usage non médical du protoxyde d’azote. Lisez le communiqué complet ci-dessous :

Abuse and misuse of second-generation antipsychotics: an analysis using VigiBase TM , the World Health Organisation pharmacovigilance database

Roy S, Charreteur R, Peries M, Kheloufi F, Eiden C, Nagot N, Donnadieu-Rigole H, Micallef J, Peyrière H. Abuse and misuse of second-generation antipsychotics: an analysis using VigiBase TM , the World Health Organisation pharmacovigilance database. Br J Clin Pharmacol. 2022 May 27. doi: 10.1111/bcp.15420. Epub ahead of print. PMID: 35633029.  

Augmentation de l’abus de méthylphénidate : repérage et profils sur 13 années

Guerra C, Soeiro T, Lacroix C, Jouve E, Micallef J, Frauger E. Augmentation de l’abus de méthylphénidate : repérage et profils sur 13 années [Increasing methylphenidate abuse: Tracking and profiles during 13-years]. Therapie. 2022 Apr 26:S0040-5957(22)00066-X. French. doi: 10.1016/j.therap.2022.03.006. Epub ahead of print. PMID: 35599193.

Perception of the Regulatory Change for Zolpidem Prescription by French General Practitioners and Its Relation to Prescription Behavior

Laforgue EJ, Istvan M, Schreck B, Mainguy M, Jolliet P, Grall-Bronnec M, Victorri-Vigneau C. Perception of the Regulatory Change for Zolpidem Prescription by French General Practitioners and Its Relation to Prescription Behavior. J Clin Med. 2022 Apr 13;11(8):2176. doi: 10.3390/jcm11082176. PMID: 35456269; PMCID: PMC9032177.

Retour haut de page